Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:CMMBNASDAQ:CNSPNASDAQ:IMNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.76-2.8%$1.72$1.23▼$4.84$16.57M0.71393,089 shs140,805 shsCMMBChemomab Therapeutics$1.37-2.1%$1.21$0.78▼$2.55$19.67M0.55211,852 shs143,547 shsCNSPCNS Pharmaceuticals$1.05-2.8%$1.18$0.77▼$637.25$3.09M2.67681,644 shs259,266 shsIMNNImunon$1.52-33.0%$0.89$0.37▼$3.65$26.66M1.753.14 million shs22.25 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-2.76%-4.35%-0.56%-29.03%-38.03%CMMBChemomab Therapeutics-2.14%-0.72%+2.24%-15.43%+50.75%CNSPCNS Pharmaceuticals-2.78%-13.93%0.00%-56.61%-99.80%IMNNImunon-33.04%+280.76%+76.74%+87.65%+4.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI1.6758 of 5 stars0.05.00.00.03.62.50.0CMMBChemomab Therapeutics3.7496 of 5 stars3.55.00.00.04.11.71.3CNSPCNS Pharmaceuticals1.358 of 5 stars3.32.00.00.02.70.00.0IMNNImunon1.8072 of 5 stars3.42.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/ACMMBChemomab Therapeutics 3.00Buy$8.50520.44% UpsideCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,280.95% UpsideIMNNImunon 2.75Moderate Buy$15.50919.74% UpsideCurrent Analyst Ratings BreakdownLatest CNSP, CMMB, BFRG, and IMNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025IMNNImunonD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.005/13/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $17.005/7/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.003/26/2025IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/25/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/24/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K276.17N/AN/A$0.43 per share4.09CMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/A($35.66) per shareN/AIMNNImunon$500K53.33N/AN/A$1.42 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.81N/A∞N/AN/A-141.39%-124.63%N/ACMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/ACNSPCNS Pharmaceuticals-$18.85M-$3,748.50N/A∞N/AN/AN/A-515.32%8/12/2025 (Estimated)IMNNImunon-$19.51M-$1.36N/AN/AN/AN/A-230.05%-128.98%8/13/2025 (Estimated)Latest CNSP, CMMB, BFRG, and IMNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/12/2025Q1 2025IMNNImunon-$0.35-$0.28+$0.07-$0.28N/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90CMMBChemomab TherapeuticsN/A4.574.57CNSPCNS PharmaceuticalsN/A1.821.82IMNNImunonN/A2.302.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%CMMBChemomab Therapeutics46.05%CNSPCNS Pharmaceuticals14.02%IMNNImunon4.47%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%CMMBChemomab Therapeutics11.91%CNSPCNS Pharmaceuticals0.07%IMNNImunon5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableCNSPCNS Pharmaceuticals52.94 million57.45 millionNot OptionableIMNNImunon3017.54 million13.78 millionNot OptionableCNSP, CMMB, BFRG, and IMNN HeadlinesRecent News About These CompaniesImunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M MoreMay 29 at 12:57 AM | insidermonkey.comIMUNON’s Stacy Lindborg on the long road to Phase IIIMay 28 at 11:32 PM | thepharmaletter.comIMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 28 at 11:32 PM | finance.yahoo.comTop Penny Stocks To Follow Now - May 26thMay 28 at 4:03 AM | americanbankingnews.comImunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News SoonMay 28 at 12:07 AM | msn.comImunon announces up to $9.75M private placement priced at-the-marketMay 27 at 7:05 PM | finance.yahoo.comIMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025May 27 at 8:05 AM | globenewswire.comPenny Stocks Worth Watching - May 25thMay 27 at 4:05 AM | americanbankingnews.comIMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced ...May 25, 2025 | seekingalpha.comImunon ovarian cancer prospect impresses with survival benefitsMay 24, 2025 | bioworld.comImunon shares soar on promising ovarian cancer trial resultsMay 23, 2025 | investing.comBiotech Stock Surges To Close The Week After Major AnnouncementMay 23, 2025 | msn.comDNA-Based Immunotherapy IMNN-001 Shows Survival Gains in Advanced Ovarian CancerMay 23, 2025 | healthandpharma.netIMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 23, 2025 | globenewswire.comImunon, Inc.: IMUNON Announces Withdrawal of Form S-1 Registration StatementMay 23, 2025 | finanznachrichten.deIMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian CancerMay 23, 2025 | globenewswire.comRetail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’May 23, 2025 | msn.comRetail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’May 23, 2025 | msn.comIMUNON Announces Withdrawal of Form S-1 Registration StatementMay 22, 2025 | globenewswire.comImunon (NASDAQ:IMNN) Downgraded to "Hold" Rating by D Boral CapitalMay 22, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNSP, CMMB, BFRG, and IMNN Company DescriptionsBullfrog AI NASDAQ:BFRG$1.76 -0.05 (-2.76%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.78 +0.02 (+1.42%) As of 05/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Chemomab Therapeutics NASDAQ:CMMB$1.37 -0.03 (-2.14%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.39 +0.02 (+1.75%) As of 05/28/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.CNS Pharmaceuticals NASDAQ:CNSP$1.05 -0.03 (-2.78%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.08 +0.02 (+2.38%) As of 05/28/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Imunon NASDAQ:IMNN$1.52 -0.75 (-33.04%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.79 +0.27 (+17.70%) As of 05/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
